Part 2 – Coronary angiography with gadofosveset trisodium: a prospective intra-subject comparison for dose optimization for 100 % efficiency imaging

Mark A. Ahlman1*, Fabio S. Raman1,2, Jianing Pang3, Filip Zemrak4, Veit Sandfort1, Scott R. Penzak5, Zhaoyang Fan3, Songtao Liu1, Debiao Li3 and David A. Bluemke1

Abstract

**Background:** Three tesla (3T) coronary magnetic resonance angiography (MRA) may be optimized using gadolinium-based contrast agents (GBCA) such as gadofosveset trisodium. The goal of this study was to evaluate if there is a qualitative or quantitative improvement in the coronary arteries with variation in contrast dose.

**Methods:** Twenty-eight healthy volunteers were prospectively recruited for coronary MRA at 3T using a steady state injection technique for 3D radial whole-heart image acquisition with retrospective respiratory self-gating (ClinicalTrials.gov identifier: NCT01853592). Nineteen volunteers completed both single- and double-dose imaging instances (0.03 and 0.06 mmol/kg, respectively). Intra-individual comparison of image quality was assessed by measurement of apparent signal/contrast-to-noise ratio (aSNR/aCNR) and subjective evaluation of image quality by 2 independent reviewers.

**Results:** The average duration of coronary MRA acquisition was 7.2 ± 1.2 min. There was significantly higher (60 %, \( p < 0.001 \)) aSNR of the aorta and right/left ventricle for the double dose compared to single dose injection scheme and aSNR of the coronary arteries increased by 70 % (\( p < 0.001 \)) for the double dose injection. aCNR increased by +55 % and +60 % in the ventricles and coronary arteries, respectively (\( p < 0.001 \)). Overall segmental artery visualization for single dose was possible 47 % of the time, which improved to 60 % with double dose (\( p = 0.019 \)), predominantly driven by improvements in more distal segment visualization (+40 % improvement in mid arterial segments, \( p = 0.013 \)).

**Conclusions:** Gadofosveset trisodium dose of 0.06 mmol/kg significantly quantitatively and qualitatively improves the coronary artery image quality compared to 0.03 mmol/kg at 3T for moderate duration (6–8 min) steady state contrast enhanced coronary MRA.

**Keywords:** Gadofosveset trisodium, MS-325, Gadolinium-based intravascular contrast agent, Whole-heart coronary magnetic resonance angiography, Navigator-based angiography, 3.0 Tesla, Image quality, Respiratory motion correction
Background
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality in the world. CT coronary angiography (CCTA) is the reference standard for non-invasive cross-sectional imaging of the coronary arteries. Coronary MRA can often be combined with venography, and comprehensive evaluation of myocardial function and structure. In addition, concerns regarding iodinated contrast allergy or concerns about ionizing radiation make coronary MRA appealing [1, 2]. However, coronary MRA remains technology challenging, especially at 3 Tesla compared to CCTA [3]. Therefore, further optimization is needed.

In general, coronary MRA has long scan times (5–15 min) because high resolution, wide spatial coverage and prospective respiratory gating via a diaphragmatic navigator has been required. Steady state free precession (SSFP) imaging is effective at defining coronary anatomy at 1.5T [4]. However at 3T, B0 and B1 field inhomogeneity and specific absorption rate (SAR) considerations result in limitations for a noncontrast approach. Contrast enhanced whole-heart imaging utilizing an inversion recovery technique is an alternative [5]. Long scan duration precludes the use of extracellular GBCAs, which have very short intravascular residence times (less than 1 min). An alternative approach uses an intravascular contrast agent such as gadofosveset trisodium (Ablavar®, Lantheus Medical Imaging, North Billerica, MA, USA). Gadofosveset has a high affinity for albumin, which resides predominately in the intravascular compartment, thus resulting in much longer enhancement of blood vessels compared to conventional extravascular MRI contrast agents (~10 min vs. 30 s, respectively) [6]. Gadofosveset has been validated at 1.5T for angiography of aortoiliac atherosclerotic disease using a dose of 0.03 mmol/kg [4, 7]. However, unlike the relatively motion-free aorta and iliac arteries, coronary MRA is complicated by the need to account for cardiac and coronary artery motion. Thus, the optimal dose of gadofosveset for coronary MRA at 3T had not been determined. For peripheral MRA, so-called “double-doses” of conventional GBCAs have shown to significantly increase raw signal intensity, SNR, and CNR [8, 9]. Double dosing is also commonly applied to cardiac MRA [10].

Advances in coronary whole-heart MRA acquisition with 100 % gating efficiency reduces acquisition time for coronary MRA by a factor of 2.5 to 3 or more [11, 12]. Thus, a coronary MRA duration of less than 10 min mimics our initial development of peripheral contrast enhanced MRA that was optimized for this timing with gadofosveset, intended for use in “double dose” gadolinium injection schemes [13].

The primary purpose of this study was to determine if the diagnostic quality and image characteristics of contrast-enhanced coronary magnetic resonance angiography (MRA) at 3T is improved by using a higher dose of gadofosveset combined with 100 % efficient whole heart coronary MRA. A secondary goal was to assess the patient tolerance and safety of the high versus low dose gadofosveset injection scheme.

Methods
Study population
Following approval by the National Heart, Lung, and Blood Institute institutional review board at the National Institutes of Health (NCT01853592), 28 subjects were recruited with written informed consent. Subjects were included between the ages of 18–45. Exclusion criteria contained standard MRI safety criteria, pregnancy, GBCA administration within 30 days, history of severe asthma, diagnosis of CAD, liver or kidney failure, and history of arrhythmia. After a focused history and physical exam, serum human chorionic gonadotropin and creatinine were drawn to exclude pregnancy or kidney failure, respectively. A complete blood count was drawn to screen for blood dyscrasia or other hematologic abnormality. Immediately prior to imaging, weight, height, heart rate, and blood pressure were recorded.

MR angiography
Standard gadofosveset dosing followed the package insert for a single dose of 0.12 mL/kg (0.03 mmol/kg), whereas the double dose protocol used 0.24 mL/kg (0.06 mmol/kg). Using a previously validated dual-injection technique specific to gadofosveset [13], the dose was diluted to 50 mL with normal saline. A more rapid injection (1.5 mL/sec) phase was immediately followed by a continuous slow infusion (0.04 mL/sec), designed to maintain steady-state intravascular concentration. The rapid/slow infusion volume ratio was 60 %/40 %. All exams used a single Spectris Solaris EP (MEDRAD Inc., Pittsburgh, PA, USA) GBCA injector. Subjects underwent the double dose protocol, a 30-day waiting period, and the single dose protocol. If heart rate was greater than 70 beats per min prior to imaging, patients received up to 100 mg oral metoprolol tartrate (Mylan Pharmaceuticals, Canonsburg, Pennsylvania, USA).

MR data was collected using a 3T MAGNETOM Verio (Siemens Medical Solutions, Erlangen, Germany) with a 32 channel receiver coil array using a contrast-enhanced, free-breathing, electrocardiogram (ECG)-gated, fat-saturated and inversion-recovery prepared spoiled gradient echo sequence with the following parameters: TE/TR = 3.5/1.8 ms, inversion time = 350 ms, bandwidth = 704 Hz/pixel, field of view = 400³ mm³, matrix size = 384³, 3D radial k-space trajectory, number of projections = 12,000. The trigger delay and acquisition window length in ECG gating were set according to the mid-diastolic quiescent period. No prospective
respiratory motion-corrected gating was performed. Rather, respiratory motion-corrected reconstruction was performed retrospectively offline using a previously validated method, whereby the raw MR data was binned into respiratory phases based on the self-navigation projections, and the respiratory motion was corrected using an image-based registration approach [11, 12].

Immediately following imaging, the subjects were asked open-ended questioning regarding any uncomfortable side effects due to contrast infusion, which were subjectively graded by the participant on a scale of 0 (none) to 10 (severe).

**Image processing and analysis**

Using Osirix™ version 5.8.5 (Pixmeo SARL, Geneva, Switzerland), the aSNR and aCNR were calculated in reference to the myocardium by drawing large regions of interest (ROI) in the left ventricle (242 ± 64 mm$^2$), right ventricle (184 ± 62 mm$^2$), descending aorta (75 ± 22 mm$^2$), and ascending aorta (163 ± 65 mm$^2$). Likewise, a smaller ROI was drawn for the coronary left main (LM) artery in the same plane that it branched from the ascending aorta (6 ± 2 mm$^2$). However, as the spatial resolution limited accurate ROIs being drawn for coronary arterial lumen, aSNR and aCNR values were obtained by averaging individual pixel densities of three pixels within the proximal arterial lumen (pixel size = 1.04 mm$^2$) for the right coronary artery (RCA), left anterior descending (LAD), and left circumflex (LCX) coronary arteries. For the reference myocardium, three separate ROIs were drawn over the septum (each 12 ± 1.4 mm$^2$) in the two-chamber view and signal intensities were averaged. Similarly, background air intensity was calculated using a large ROI superior to the chest cavity (25.5 ± 11.4 cm$^2$). The equations used to calculate aSNR and aCNR (relative to myocardium) were then used as follows (SI – Signal Intensity, SD – Standard Deviation):

$$aSNR = \frac{SI_{vessel}}{SD_{air}}$$

$$aCNR = \frac{SI_{vessel} - SI_{myocardium}}{SD_{air}}$$

Two cardiologists experienced in coronary imaging (FZ, VS) performed blinded independent review of the coronary arteries for diagnostic quality in the LAD, LCX, and RCA in the proximal and mid portions of the artery. To measure overall difference in quality between dosing attempts, image quality was reported using a qualitative scale of 0 (artery segment not visualized), and 1 (visualized). For measurements of inter- and intra-reader agreement, a more gradated categorical scale was used: 0, not interpretable; 1, poor (severe artifacts); 2, good (mild to moderate artifacts); 3, very good (minimum to mild artifacts); 4, excellent (minimum or no artifacts).

Using a higher (0.05 mmol/kg) dose of Gadofosveset, prior studies have observed an approximately 50 % increase in CNR and 40 % increase in SNR in the peripheral and central vasculature compared to the standard 0.03 mmol/kg dosing scheme [14]. In a similar fashion, we separately evaluated aCNR and aSNR for gadofosveset coronary angiography [15]. Using this a priori information, we determined sample size for a paired comparison with beta = 0.8 and alpha = 0.05 to detect a 50 % increase in aCNR, and 40 % increase in aSNR for 0.06 mmol/kg compared to 0.03 mmol/kg gadofosveset. 19 subjects provided at least 80 % power; additional subjects were recruited to account for potential subject withdrawal prior to completion of two MRI scans.

Significant differences in quantitative and qualitative image quality parameters were calculated using Wilcoxon matched-pairs signed rank test. The intra- and inter-class correlation coefficient (ICC) was calculated for per-segment qualitative scores for single readers and between readers. Chi square analysis was performed for the determination if there was a higher proportion and severity of side effects due to double dosing among subjects who completed both single and double dose instances. Statistical significance was considered to have a p-value < 0.05. Differences in demographic, physiologic, and lab parameters between single dose and double dose scanning were compared with the Mann–Whitney or Chi square test, where appropriate.

**Results**

**Study population**

With demographics shown in Table 1, 22 of 28 subjects recruited were able to complete the initial double-dose imaging, of which, 19 completed the follow up single-dose imaging. A total of 9 subjects met exclusion criteria during the protocol because of: pre-screening lab values out of the normal range (4 subjects), lack of adequate intravenous access (1 subject), self-withdrawal prior to imaging (1 subject), or loss to follow-up following the initial MRI (3 subjects).

MRA imaging time for double and single dose instances was not significantly different, with an overall average of 7.2 ± 1.2 min.

**Quantitative evaluation**

Shown in Table 2, there were uniform, statistically significant increases in aSNR for all regions measured. aCNR also increased for all segments with the exception of the LCX ($p = 0.09$). Overall, there was an approximate 60 % increase in aSNR of the aorta and ventricles ($p < 0.001$) and an approximate 70 % increase ($p < 0.001$) in the coronary arteries. There was a similar increase in aCNR of...
the aorta/ventricles and coronary arteries, representing approximately +55 % (p < 0.001) and +60 % (p < 0.001), respectively.

### Qualitative evaluation

Shown in Table 3, there were statistically significant improvements in qualitative vessel measurements with double dosing. Improvement was evidenced primarily in the mid portions of the artery (+40.6 %, p = 0.013). Although there was a uniform trend for an increase in vessel identification for all segments measured, statistically significant changes were not shown for the proximal LCX and proximal and distal RCA. With all proximal and mid segments included for evaluation, the overall vessel identification at single dose was 0.47 ± 0.27, which improved to 0.60 ± 0.25. The intra-and inter-class correlation coefficients were high for proximal coronary artery segments (ICC >0.7), with mixed results in the mid to distal segments.

Images representative of a perceptible visual difference in image quality between the single and double dosing protocol is shown in Fig. 1. Curved multiplanar reconstruction and 3-dimensional volume surface reconstruction of the heart using the double dose protocol are shown in Figs. 2 and 3, respectively.

### Side effect severity

Following the initial double dose injection, one subject was excluded from further study because of the feeling of self-limiting “throat tightening” and throat pruritus. A second subject did not return for single dose scanning for undisclosed reasons. Of patients completing both examinations, more patients reported side effects of at least 1 out of 10 severity for double dose compared to single dose injection (65 % vs 42 %, p < 0.0001). Symptom severity was also higher (p < 0.0001) in double dose compared to single dose injection with a mean of

### Table 1 Subject demographics

|                      | Single dose (n = 19) | Double dose (n = 22) | P value |
|----------------------|----------------------|----------------------|---------|
| Age                  | 29.6 ± 6.8           | 29.1 ± 6.7           | NS      |
| Male                 | 26.3 % (5/19)        | 22.7 % (5/22)        | NS      |
| Height (cm)          | 165.4 ± 7.5          | 165.9 ± 7.3          | NS      |
| Weight (kg)          | 71.6 ± 20.2          | 70.9 ± 19.2          | NS      |
| Body mass index (kg/m²) | 26.0 ± 6.2          | 25.6 ± 5.9           | NS      |
| Hematocrit (%)       | 41.1 ± 5.6           | 40.7 ± 6.1           | NS      |
| Creatine (mg/dL)     | 0.81 ± 0.16          | 0.80 ± 0.15          | NS      |
| eGFR (mL/min/1.73 m²)| 113.0 ± 11.6         | 107.8 ± 12.1         | NS      |
| Heart rate (bpm)     | 66.7 ± 7.0           | 66.1 ± 11.0          | NS      |
| Systolic blood pressure (mmHg) | 117.6 ± 11.5       | 117.1 ± 12.1         | NS      |
| Diastolic blood pressure (mmHg) | 72.3 ± 9.9          | 70.1 ± 10.6          | NS      |
| Imaging Parameters   |                      |                      |         |
| Dose (mL)            | 8.6 ± 2.4            | 17.1 ± 4.7           | <0.001  |
| Imaging time (min)   | 68 ± 1.2             | 7.5 ± 1.2            | NS      |
| Non significant      |                      |                      |         |

### Table 2 Quantitative aSNR and aCNR evaluation

| Level          | aSNR          | aCNR          |
|----------------|---------------|---------------|
|                | Single dose   | Double dose   | P value | Single dose | Double dose | P value |
| Left Ventricle |               |               |         |             |             |         |
|                | 11.0 ± 4.5    | 17.3 ± 7.8    | <0.001  | 6.0 ± 2.7   | 9.0 ± 5.0   | 0.002   |
| Right Ventricle| 10.7 ± 8.4    | 16.7 ± 11.7   | <0.001  | 5.7 ± 6.8   | 8.4 ± 9.2   | 0.006   |
| Desc. Aorta    | 9.5 ± 4.0     | 15.6 ± 8.1    | <0.001  | 4.5 ± 2.9   | 7.2 ± 5.5   | 0.01    |
| Prox. Aorta    | 13.1 ± 6.1    | 21.9 ± 10.6   | <0.001  | 8.1 ± 4.5   | 13.6 ± 7.7  | <0.001  |
| Overall        | 11.1 ± 6.0    | 17.9 ± 9.8    | <0.001  | 6.1 ± 4.6   | 9.5 ± 7.3   | <0.001  |
| LMS            | 10.5 ± 4.8    | 18.2 ± 8.1    | <0.001  | 5.4 ± 3.6   | 9.6 ± 6.4   | 0.002   |
| LAD            | 14.5 ± 4.3    | 23.6 ± 8.7    | <0.001  | 9.0 ± 3.7   | 14.1 ± 8.3  | 0.02    |
| LCX            | 10.7 ± 3.5    | 16.5 ± 4.3    | <0.001  | 5.5 ± 3.1   | 7.8 ± 4.5   | 0.09    |
| RCA            | 15.5 ± 6.6    | 25.3 ± 11.0   | <0.001  | 10.4 ± 5.1  | 16.7 ± 10.0 | 0.01    |
| Overall        | 12.8 ± 5.4    | 21.0 ± 9.1    | <0.001  | 7.6 ± 4.5   | 12.1 ± 8.3  | <0.001  |
| Myocardium     | 4.9 ± 2.3     | 8.3 ± 3.8     | <0.001  |             |             |         |

There is higher aSNR and aCNR with double dose gadofosveset aSNR Apparent signal-to-noise ratio aCNR Apparent Contrast-to-noise ratio (relative to the myocardium) LM Left main coronary artery LAD Left anterior descending coronary artery LCX Left circumflex coronary artery RCA Right coronary artery
### Table 3 Qualitative evaluation

| Level        | Mean image quality | Wilcoxon ICC | Δ % | P value | Intra | Inter |
|--------------|--------------------|--------------|-----|---------|-------|-------|
|              | Single dose        | Double dose  |     |         |       |       |
| LAD<sub>prox</sub> | 0.65 ± 0.40        | 0.89 ± 0.26  | 36.9| 0.004   | 0.77  | 0.81  |
| LAD<sub>mid</sub>  | 0.48 ± 0.33        | 0.60 ± 0.29  | 25.0| 0.048   | 0.44  | 0.7   |
| LCX<sub>prox</sub> | 0.52 ± 0.39        | 0.62 ± 0.40  | 19.2| NS      | 0.73  | 0.76  |
| LCX<sub>mid</sub>  | 0.14 ± 0.25        | 0.33 ± 0.35  | 135.7| 0.020   | 0.6   | 0.51  |
| RCA<sub>prox</sub> | 0.68 ± 0.38        | 0.69 ± 0.40  | 1.5 | NS      | 0.87  | 0.79  |
| RCA<sub>mid</sub>  | 0.33 ± 0.24        | 0.43 ± 0.38  | 30.3| NS      | 0.48  | 0.61  |
| Overall<sub>prox</sub> | 0.62 ± 0.36        | 0.73 ± 0.29  | 17.7| NS      | -     | -     |
| Overall<sub>mid</sub> | 0.32 ± 0.22        | 0.45 ± 0.27  | 40.6| 0.013   | -     | -     |
| Overall<sub>prox+mid</sub> | 0.47 ± 0.29        | 0.60 ± 0.25  | 27.7| 0.019   | -     | -     |

Double dosing results in higher per-segment image quality of arterial segments. Statistically significant changes are shown in bold.

LAD Left anterior descending coronary artery
LCX Left circumflex coronary artery
RCA Right coronary artery
prox Proximal
mid Middle

**Fig. 1** Visual comparison of image quality with double dose. Double dose (left column) and single dose (right column) maximum intensity projection MRA images of the heart for two subjects (top and bottom rows). Visually compared to single dose images (b and d), double dose images (a and c) show appreciably higher image quality of the LAD (white arrow), RCA (white arrowhead), and LCX arteries (black arrow). Window and level is fixed for representative image comparisons per subject.
2.83 ± 2.61 and 1.13 ± 1.80, respectively. Ranked in order of occurrence, the most common reported side effects are shown in Table 4.

**Discussion**

At 3.0-Tesla field strength, contrast-enhancement of the coronary arteries has been explored for MRA [5] and gadofosveset has shown promise in this application [16]. Previous use of gadofosveset in coronary MRA has shown a small increase in image quality compared to the more conventional MR contrast agents [15]. Furthermore, the long intravascular residence time and high T1 relaxivity may afford improvements in self-navigated respiratory motion compensation [17]. This strategy with gadofosveset is desirable for the 3D radial protocol used in this study as each k-space line contributes equally to the image contrast; therefore a stable contrast enhancement throughout the scan duration is desired. Additional diagnostic improvements with higher doses of gadofosveset have not been systematically evaluated with these advanced reconstruction techniques. Our results found higher aSNR and aCNR, as well as superior image quality represented by higher qualitative yield, particularly in the mid arterial segments. Our finding of significant increases in the more distal segments may be expected because of the opportunity to increase the

| Times reported | Event                                      | Attribution to gadofosveset or saline injection | Expected |
|----------------|--------------------------------------------|-------------------------------------------------|----------|
| 12             | Pelvic tingling                            | Probable                                       | Yes      |
| 9              | Pelvic itching                             | Probable                                       | Yes      |
| 6              | Arm chill/coldness/numbness/tingling        | Probable                                       | Yes      |
| 5              | nausea                                     | Probable                                       | Yes      |
| 3              | Nasal congestion                           | Unlikely                                       | No       |
| 2              | Metallic taste                             | Probable                                       | Yes      |
| 2              | Saline smell                               | Probable                                       | Yes      |
| 2              | Increased salivation                       | Probable                                       | Yes      |
| 2              | Warm body sensation                        | Probable                                       | Yes      |
| 1              | Pelvic pressure                            | Probable                                       | Yes      |
| 1              | Pelvic discomfort                          | Probable                                       | Yes      |
| 1              | Low back pain                              | Unlikely                                       | No       |
| 1              | Prickly sensation                          | Probable                                       | Yes      |
| 1              | Cold body sensation                        | Probable                                       | Yes      |
| 1              | Tingling body sensation                    | Probable                                       | Yes      |
| 1              | Reflux sensation                           | Unlikely                                       | No       |
| 1              | Throat itching                             | Probable                                       | Yes      |
| 1              | Throat irritation                          | Probable                                       | Yes      |

More than one symptom could be reported by a single participant.
otherwise poor luminal signal intensity at these levels because of small vessel caliber, compared to the proximal segments where single dose may suffice for visualization of the larger caliber artery at this level. Nonetheless, our results did show a statistically significant qualitative improvement in the proximal LAD. Despite a uniform trend for improved aCNR, aSNR, and qualitative measurement with double dose across all vascular territories, statistical significance was lacking in qualitative measurement in the LCx and RCA territory and with aCNR of the LCx, which may be due to limitations in field homogeneity, higher regional respiratory or cardiac motion, or limitations in sample size. With the intent for a robust evaluation of the entire coronary arterial tree with MR, there is promise in the combination of a higher dosing of gadofosveset along with other improvements in image acquisition [18].

Regarding the technique of coronary MRA with gadofosveset, we were able to target the image acquisition for the mid-diastolic quiescent period prior to contrast injection. Anecdotally, we observed an increase in the heart rate just after injection (5–15 beats per minute increase), which may have altered the mid-diastolic rest phase timing relative to the pre-planning cine images. In this regard, further improvements in image quality may follow with real-time adaptation to heart rate changes or other methods to mitigate the effect of heart rate variability [19], in addition to stabilization of heart rate with beta blockade [20].

Double dose injection protocols appear to predominate in current practice for cardiac MRI [10]. Increased risk of nephrogenic systemic sclerosis (NSF) as well as patient comfort are factors to consider for dose increases of gadolinium-based contrast agents [21]. We did not evaluate the long term safety of our dosing scheme, although gadofosveset safety of 0.03, 0.05, and 0.07 mmol/kg dosing has been previously reported [7]. Although patients reported an increase in the side effects of the higher dose of gadofosveset in this study, we did not observe severe contrast reactions for either dosing scheme. Because any abnormal liver or kidney function measurement resulted in exclusion from participation, the safety of higher doses of gadofosveset for patients with health complications is not evaluated here.

Conclusions
The use of double doses of gadofosveset trisodium results in higher qualitative and quantitative image quality compared to the standard single dose. In combination with further improvements in technique, double dosing shows promise for use in coronary MR angiography at 3.0 Tesla. Diagnostic efficacy could be further evaluated to determine whether the superior image quality allows better assessment of coronary structural abnormalities in atherosclerotic patients.

Abbreviations
3T: 3.0 Tesla; aCNR: apparent contrast-to-noise ratio; aSNR: apparent signal-to-noise ratio; CAD: coronary artery disease; CCTA: computed tomography coronary angiography; ECG: electrocardiogram; GBCA: gadolinium-based contrast agent; LAD: left anterior descending; LCx: left circumflex; LM: left main; Mid: middle; MR: magnetic resonance; MRA: magnetic resonance angiography; Myo: myocardium; NS: non significant; Prox: proximal; RCA: right coronary artery; ROI: region of interest; SD: standard deviation; SI: signal intensity.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MAA, FSR, JP, FZ, VS, ZF, SL: study design, data acquisition, data analysis, data interpretation, manuscript drafting; DL, DAB: principal investigators, study design, data interpretation, and manuscript revision. All authors read and approved the final manuscript.

Acknowledgements
The National Institutes of Health (NIH) intramural research program and the imaging sciences training program supported this research. We thank Jacquin Jones who provided scheduling and recruitment services for the work herein.

Author details
1National Institutes of Health, Radiology and Imaging Sciences, Clinical Center, 10 Center Drive, Building 10, Rm B1N264B.7, Bethesda, MD 20892, USA.
2Medical Scientist Training Program, University of Alabama at Birmingham, Birmingham, AL, USA.
3Bioengineering, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
4William Harvey Research Institute, Centre for Advanced Cardiovascular Imaging, Bart’s & The London School of Medicine & Dentistry, London, UK.
5Department of Pharmacotherapy, University of North Texas, Fort Worth, Texas, USA.

Received: 14 May 2015 Accepted: 18 November 2015
Published online: 22 March 2016

References
1. Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gones AS, et al. Ionizing radiation in cardiac imaging. Circulation. 2009;119:1056–65.
2. Namazivayam S, Kalra MK, Torres WE, Small WC. Adverse reactions to intravenous iodinated contrast media: a primer for radiologists. Emerg Radiol. 2006;12(5):210–5.
3. Nikolau K, Alkadhi H, Bamberg F, Leshka S, Wintersperger BJ. MRI and CT in the diagnosis of coronary artery disease: indications and applications. Insights into imaging. 2011;2(1):9–24.
4. Goyen M, Edelman M, Pereau P, O’Riordan E, Bertoni H, Taylor J, et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology. 2005;236:825–33. doi:10.1148/radiol.2363040577.
5. Yang Q, Li K, Liu X, Bi X, Liu Z, An J, et al. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0-T: a comparative study with X-ray angiography in a single center. J Am Coll Cardiol. 2009;54(1):69–76.
6. Frydychowicz A, Russe MF, Bock J, Stalder AF, Bley TA, Harloff A, et al. Comparison of gadofosveset trisodium and gadobenate dimeglumine during time-resolved thoracic MR angiography at 3T. Acad Radiol. 2010;17:1394.
7. Pereau P, Edelman MA, Baum RA, Yucel EK, Weiskoff RM, Shamsi K, et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology. 2003;229:811–20.
8. Hayashi H, Yusa A, Yano Y, Tanimoto A, Saito Y, Yoshikawa K, et al. Arterial visualization by contrast-enhanced moving-table MR angiography: crossover comparison of 0.1 and 0.2 mmol/kg doses of meglumine gadopentetate in normal volunteers. J Magn Reson Imaging. 2008;28(3):783–90. doi:10.1002/jmri.21488.
9. Heverhagen JT, Wright CL, Schmalbrock P, Knopp MV. Dose comparison of single versus double dose in contrast-enhanced magnetic resonance angiography of the renal arteries: intra-individual cross-over blinded trial using Gd-DTPA. Eur Radiol. 2009;19(1):67–72. doi:10.1007/s00330-008-1120-9.
10. Nacif MS, Ara AE, Lima J, Bluemke DA. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. J Cardiovasc Magn Reson. 2012;14:1418.

11. Pang J, Bhat H, Sharif B, Fan Z, Thomson LE, LaBounty T, et al. Whole-heart coronary MRA with 100 % respiratory gating efficiency: Self-navigated three-dimensional retrospective image-based motion correction (TRIM). Magn Reson Med. 2014;71(1):67–74.

12. Pang J, Sharif B, Arsanjani R, Bi X, Fan Z, Yang Q, et al. Accelerated whole-heart coronary MRA using motion-corrected sensitivity encoding with three-dimensional projection reconstruction. Magn Reson Med. 2014.

13. Ahlman MA, Raman FS, Penzak SR, Pang J, Li D, Bluemke D. Optimization of gadofosveset intravenous injection scheme for coronary MRA: the pharmacokinetics approach. J Cardiovasc Magn Reson. 2014;16 Suppl 1:160.

14. Maki JH, Wang M, Wilson GJ, Shutks MG, Leiner T. Highly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents. J Magn Reson Imaging. 2009;30(5):1085–92.

15. Raman FS, Nacif MS, Catr G, Gai N, Jones J, Li D, et al. 3.0 T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging. 2013;29(5):1085–94.

16. Kelle S, Thouet T, Tangcharoen T, Nassenstein K, Chiribiri A, Paetsch J, et al. Whole-heart coronary magnetic resonance angiography with MS-325 (Gadofosveset). Med Sci Monit. 2007;13:CR469–74. doi:10.12687.

17. Prompona M, Cyran C, Nikolaou K, BAuer K, Reiser M, Huber A. Contrast-enhanced whole-heart coronary MRA using Gadofosveset 3.0 T versus 1.5 T. Acad Radiol. 2010;17:862–70. doi:10.1016/j.acra.2010.02.009.

18. Malayeri AA, Macedo R, Li D, Chen S, Rahmani H, Lai S, et al. Coronary vessel wall evaluation by magnetic resonance imaging in the multi-ethnic study of atherosclerosis: determinants of image quality. J Comput Assist Tomogr. 2009;33(1):1.

19. Pang J, Sharif B, Fan Z, Bi X, Arsanjani R, Berman DS, et al. ECG and navigator-free four-dimensional whole-heart coronary MRA for simultaneous visualization of cardiac anatomy and function. Magn Reson Med. 2014;72(5):1208–17.

20. Jahnke C, Paetsch I, Achenbach S, Schnackenburg B, Gekeler R, Fleck E, et al. Coronary MR imaging: breath-hold capability and patterns, coronary artery rest periods, and beta-blocker use. Radiology. 2006;239(1):71–8. doi:10.1148/rad.2383042019.

21. Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:31.